Groupama Asset Managment Boosts Position in Thermo Fisher Scientific Inc. $TMO

Groupama Asset Managment boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.9% during the 1st quarter, HoldingsChannel reports. The firm owned 145,799 shares of the medical research company’s stock after purchasing an additional 18,919 shares during the period. Groupama Asset Managment’s holdings in Thermo Fisher Scientific were worth $72,923,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Vanguard Group Inc. increased its position in Thermo Fisher Scientific by 0.7% in the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company’s stock worth $16,659,627,000 after buying an additional 230,382 shares in the last quarter. Northern Trust Corp grew its stake in shares of Thermo Fisher Scientific by 13.2% during the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company’s stock valued at $2,034,107,000 after acquiring an additional 455,004 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in Thermo Fisher Scientific by 86.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company’s stock worth $1,604,338,000 after acquiring an additional 1,433,444 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Thermo Fisher Scientific by 4.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company’s stock valued at $1,455,774,000 after purchasing an additional 115,463 shares in the last quarter. Finally, Pictet Asset Management Holding SA boosted its position in shares of Thermo Fisher Scientific by 7.2% in the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company’s stock worth $1,432,816,000 after purchasing an additional 193,378 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on TMO shares. Argus decreased their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a research report on Tuesday, April 29th. HSBC reissued a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Raymond James Financial reaffirmed an “outperform” rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Finally, Royal Bank Of Canada lowered their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Seven analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $593.00.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $488.15 on Tuesday. The firm has a fifty day simple moving average of $436.43 and a two-hundred day simple moving average of $458.25. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $184.33 billion, a P/E ratio of 28.23, a PEG ratio of 2.61 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the business posted $5.37 earnings per share. The firm’s revenue was up 2.9% on a year-over-year basis. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the sale, the chief executive officer owned 115,174 shares of the company’s stock, valued at $52,037,916.68. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,400 shares of company stock valued at $8,345,792 over the last ninety days. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.